Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC2592 in advanced chronic congestive heart failure
NCT00099580Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2005
- Primary completion
- Sep 2006
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of AC2592 in heart failure (HF), sponsored by AstraZeneca. Started Mar 2005; status: completed.
02
Drugs
AC2592
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT00099580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00099580.